{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:15:28Z","timestamp":1791227728299,"version":"4.1.0"},"reference-count":106,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.soc.2012.07.007","type":"journal-article","created":{"date-parts":[[2012,8,30]],"date-time":"2012-08-30T15:16:01Z","timestamp":1346339761000},"page":"645-663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Current Status and Future Directions of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Ovarian Cancer"],"prefix":"10.1016","volume":"21","author":[{"given":"C. William","family":"Helm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.soc.2012.07.007_bib1","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","article-title":"Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer\u2014shifting the paradigm","volume":"42","author":"Kurman","year":"2011","journal-title":"Hum Pathol"},{"key":"10.1016\/j.soc.2012.07.007_bib2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/path.1000","article-title":"Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer","volume":"195","author":"Piek","year":"2001","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.soc.2012.07.007_bib3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1158\/1055-9965.EPI-08-0771","article-title":"Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995-2004","volume":"18","author":"Goodman","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"55","key":"10.1016\/j.soc.2012.07.007_bib4","first-page":"74","article-title":"Global cancer statistics","volume":"2005","author":"Parkin","year":"2002","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.soc.2012.07.007_bib5","series-title":"Cancer facts & figures 2012","author":"American Cancer Society","year":"2012"},{"issue":"Suppl 1","key":"10.1016\/j.soc.2012.07.007_bib6","first-page":"S161","article-title":"Carcinoma of the ovary. FIGO 6th annual report on the results of treatment in gynecological cancer","volume":"95","author":"Heintz","year":"2006","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.soc.2012.07.007_bib7","series-title":"SEER cancer statistics review, 1975-2006","year":"2009"},{"key":"10.1016\/j.soc.2012.07.007_bib8","series-title":"Blaustein's pathology of the female genital tract","first-page":"791","article-title":"Surface epithelial tumors of the ovary","author":"Seidman","year":"2002"},{"key":"10.1016\/j.soc.2012.07.007_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1006\/gyno.2002.6711","article-title":"Long-term survival and patterns of care in women with ovarian tumors of low malignant potential","volume":"86","author":"Trimble","year":"2002","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0090-8258(90)90174-J","article-title":"Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds","volume":"36","author":"Gore","year":"1990","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.soc.2012.07.007_bib12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1525-1438.2007.01161.x","article-title":"Second-line randomized trials in epithelial ovarian cancer","volume":"18","author":"Vermorken","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.soc.2012.07.007_bib13","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S0002-9378(15)33580-8","article-title":"The changing prognosis and treatment in cancer of the ovary","volume":"100","author":"Munnell","year":"1968","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.soc.2012.07.007_bib14","first-page":"101","article-title":"Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma","volume":"42","author":"Griffiths","year":"1975","journal-title":"Natl Cancer Inst Monogr"},{"key":"10.1016\/j.soc.2012.07.007_bib15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0090-8258(92)90100-W","article-title":"The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study","volume":"47","author":"Hoskins","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib16","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib17","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1006\/gyno.2001.6312","article-title":"What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer?","volume":"82","author":"Eisenkop","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1006\/gyno.1998.4955","article-title":"Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study","volume":"69","author":"Eisenkop","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib19","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ygyno.2006.06.028","article-title":"The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer","volume":"103","author":"Eisenhauer","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib20","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ygyno.2006.11.002","article-title":"Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction","volume":"104","author":"Bristow","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib21","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/ijgc-00009577-199609000-00002","article-title":"Neoadjuvant chemotherapy for advanced ovarian cancer","volume":"6","author":"Surwit","year":"1996","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.soc.2012.07.007_bib22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00432-001-0312-3","article-title":"The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer","volume":"128","author":"Huober","year":"2002","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib23","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1245\/s10434-009-0558-6","article-title":"Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies","volume":"16","author":"Kang","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib24","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 8","key":"10.1016\/j.soc.2012.07.007_bib25","doi-asserted-by":"crossref","first-page":"viii7","DOI":"10.1093\/annonc\/mdi961","article-title":"2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)","volume":"16","author":"du Bois","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib26","unstructured":"NCCN guidelines version 2. 2012: epithelial ovarian cancer\/fallopian tube cancer\/ primary peritoneal cancer. 2012. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp. Accessed June 2, 2012."},{"key":"10.1016\/j.soc.2012.07.007_bib27","unstructured":"Helm CW, Edwards RP. Ovarian cancer treatment protocols. 2011. Available at: http:\/\/emedicine.medscape.com\/article\/2006723-overview. Accessed May 28, 2012."},{"issue":"1","key":"10.1016\/j.soc.2012.07.007_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005340.pub2","article-title":"Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer","author":"Jaaback","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.soc.2012.07.007_bib29","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1471-0528.2011.03179.x","article-title":"Ports and complications for intraperitoneal chemotherapy delivery","volume":"119","author":"Helm","year":"2012","journal-title":"BJOG"},{"key":"10.1016\/j.soc.2012.07.007_bib30","first-page":"21","article-title":"Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings","volume":"93","author":"Rubin","year":"1999","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.soc.2012.07.007_bib31","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0090-8258(03)00278-6","article-title":"Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study","volume":"90","author":"Eisenkop","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib32","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/jnci\/dji102","article-title":"Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial","volume":"97","author":"Panici","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.soc.2012.07.007_bib33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2009.03.018","article-title":"Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm","volume":"114","author":"Chi","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib34","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ygyno.2006.03.051","article-title":"What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?","volume":"103","author":"Chi","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib35","doi-asserted-by":"crossref","unstructured":"Burger RA, Brady MF, Bookman MA, et\u00a0al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. 2010;28:5s (Suppl; abstr LBA1). Abstract available at: http:\/\/www.asco.org\/ASCOv2\/Meetings\/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=52788. Accessed June 3, 2012.","DOI":"10.1200\/jco.2010.28.18_suppl.lba1"},{"key":"10.1016\/j.soc.2012.07.007_bib36","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A\u00a0phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.soc.2012.07.007_bib37","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jso.21083","article-title":"Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer","volume":"98","author":"Helm","year":"2008","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib38","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s002800050870","article-title":"A\u00a0pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer","volume":"43","author":"Steller","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.soc.2012.07.007_bib39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1048-891x.2004.14008.x","article-title":"Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum","volume":"14","author":"Look","year":"2004","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.soc.2012.07.007_bib40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-7819-2-21","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer","volume":"2","author":"Piso","year":"2004","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib41","first-page":"121","article-title":"Efficacy of intraperitoneal continuous hyperthermic chemotherapy as consolidation therapy in patients with advanced epithelial ovarian cancer: a long-term follow-up","volume":"13","author":"Yoshida","year":"2005","journal-title":"Oncol Rep"},{"key":"10.1016\/j.soc.2012.07.007_bib42","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/jso.20597","article-title":"Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer","volume":"94","author":"Rufian","year":"2006","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib43","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00268-007-9146-8","article-title":"Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients","volume":"31","author":"Cotte","year":"2007","journal-title":"World J Surg"},{"key":"10.1016\/j.soc.2012.07.007_bib44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ygyno.2007.03.022","article-title":"Intraperitoneal hyperthermic chemotherapy using carboplatin: a phase I analysis in ovarian carcinoma","volume":"106","author":"Lentz","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cncr.23553","article-title":"Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer","volume":"113","author":"Di Giorgio","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.soc.2012.07.007_bib46","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1245\/s10434-008-0299-y","article-title":"Hyperthermic intraperitoneal chemotherapy after extensive cytoreductive surgery in patients with primary advanced epithelial ovarian cancer: interim analysis of a phase II study","volume":"16","author":"Lim","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib47","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2011.05.004","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial","volume":"122","author":"Deraco","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib48","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/IGC.0b013e3181c50cde","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry","volume":"20","author":"Helm","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.soc.2012.07.007_bib49","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ygyno.2009.12.026","article-title":"Peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian peritoneal carcinomatosis: an argued role","volume":"117","author":"Di Giorgio","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib50","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/jso.20243","article-title":"Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma","volume":"90","author":"Reichman","year":"2005","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib51","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00001813-200302000-00003","article-title":"Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer","volume":"14","author":"de Bree","year":"2003","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.soc.2012.07.007_bib52","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ygyno.2004.05.044","article-title":"Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer","volume":"94","author":"Ryu","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.soc.2012.07.007_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007414.pub2","article-title":"Maintenance chemotherapy for ovarian cancer","author":"Mei","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.soc.2012.07.007_bib54","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2003.07.013","article-title":"Phase III randomized trial of 12 versus 3\u00a0months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial","volume":"21","author":"Markman","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib55","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ygyno.2009.04.012","volume":"114","author":"Markman","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib56","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2009.21.9691","article-title":"Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel\/platinum-based chemotherapy: final results of the After-6 protocol 1","volume":"27","author":"Pecorelli","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib57","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/ijgc-00009577-200311001-00012","article-title":"Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy","volume":"2","author":"Piccart","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.soc.2012.07.007_bib58","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1200\/JCO.2002.20.3.694","article-title":"Intraperitoneal chemotherapy for\u00a0ovarian carcinoma: results of long-term follow-up","volume":"20","author":"Barakat","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib59","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/gyno.1998.4973","article-title":"A\u00a0phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment","volume":"69","author":"Barakat","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib60","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0090-8258(03)00474-8","article-title":"Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission","volume":"91","author":"Tournigand","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib61","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ygyno.2007.03.019","article-title":"Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery","volume":"106","author":"Bae","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib62","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/ijgc-00009577-200503000-00008","article-title":"Intraperitoneal hyperthermic chemotherapy in ovarian cancer","volume":"15","author":"Gori","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.soc.2012.07.007_bib63","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ejso.2010.04.005","article-title":"Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study","volume":"36","author":"Pomel","year":"2010","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib64","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/jso.21732","article-title":"Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: a pilot study of 31 patients","volume":"103","author":"Frenel","year":"2011","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib65","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1006\/gyno.2001.6151","article-title":"Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer","volume":"81","author":"Bolis","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib66","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","article-title":"Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis","volume":"112","author":"Bristow","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib67","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","article-title":"Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer","volume":"95","author":"Gordon","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib69","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2002.20.5.1232","article-title":"Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens","volume":"20","author":"Cantu","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib70","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.soc.2012.07.007_bib71","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2165\/11591720-000000000-00000","article-title":"Management strategies for recurrent platinum-resistant ovarian cancer","volume":"71","author":"Naumann","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.soc.2012.07.007_bib72","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ygyno.2004.09.018","article-title":"Critical evaluation of secondary cytoreduction in recurrent ovarian cancer","volume":"95","author":"Munkarah","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib73","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1245\/s10434-009-0357-0","article-title":"Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis","volume":"16","author":"Harter","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib74","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.ejca.2006.03.025","article-title":"Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations","volume":"42","author":"Ferrandina","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.soc.2012.07.007_bib75","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1053\/ejso.2000.0978","article-title":"Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot","volume":"26","author":"van der Vange","year":"2000","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib76","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/1096-9098(200005)74:1<41::AID-JSO10>3.0.CO;2-R","article-title":"Treatment of peritoneal carcinomatosis with intent to cure","volume":"74","author":"Cavaliere","year":"2000","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib77","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/030089160108700302","article-title":"Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study","volume":"87","author":"Deraco","year":"2001","journal-title":"Tumori"},{"key":"10.1016\/j.soc.2012.07.007_bib78","first-page":"1329","article-title":"Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy","volume":"22","author":"Panteix","year":"2002","journal-title":"Anticancer Res"},{"key":"10.1016\/j.soc.2012.07.007_bib79","first-page":"3019","article-title":"Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin","volume":"23","author":"de Bree","year":"2003","journal-title":"Anticancer Res"},{"key":"10.1016\/j.soc.2012.07.007_bib80","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1055\/s-2003-44484","article-title":"Treatment of recurrent epithelial ovarian cancer with secondary cytoreduction and continuous intraoperative intraperitoneal hyperthermic chemoperfusion (CIIPHCP)","volume":"125","author":"Chatzigeorgiou","year":"2003","journal-title":"Zentralbl Gynakol"},{"key":"10.1016\/j.soc.2012.07.007_bib81","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1007\/s00268-004-7461-x","article-title":"Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer","volume":"28","author":"Zanon","year":"2004","journal-title":"World J Surg"},{"key":"10.1016\/j.soc.2012.07.007_bib82","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ejso.2006.03.011","article-title":"Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced\/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan","volume":"32","author":"Raspagliesi","year":"2006","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib83","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ygyno.2006.10.051","article-title":"Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma","volume":"105","author":"Helm","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib84","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1245\/s10434-007-9718-8","article-title":"Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy","volume":"15","author":"Harrison","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib85","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s12094-009-0438-3","article-title":"The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer","volume":"11","author":"Munoz-Casares","year":"2009","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib86","first-page":"441","article-title":"Peritoneal carcinomatosis from ovarian epithelial primary: combined aggressive treatment","volume":"23","author":"Cavaliere","year":"2009","journal-title":"In\u00a0Vivo"},{"issue":"4","key":"10.1016\/j.soc.2012.07.007_bib87","doi-asserted-by":"crossref","first-page":"E23","DOI":"10.1684\/bdc.2010.1063","article-title":"Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer","volume":"97","author":"Carrabin","year":"2010","journal-title":"Bull Cancer"},{"key":"10.1016\/j.soc.2012.07.007_bib88","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ygyno.2009.03.011","article-title":"Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review","volume":"114","author":"Gerestein","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib89","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00432-009-0667-4","article-title":"Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results","volume":"135","author":"Chua","year":"2009","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib90","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1634\/theoncologist.2008-0275","article-title":"The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer","volume":"14","author":"Helm","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.soc.2012.07.007_bib91","unstructured":"Criteria NCICT for adverse events (CTCAE) version 4.0. Available at: http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed June 3, 2012."},{"key":"10.1016\/j.soc.2012.07.007_bib92","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"10.1016\/j.soc.2012.07.007_bib93","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1245\/s10434-008-0073-1","article-title":"Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from appendix: preliminary results of a survival analysis","volume":"15","author":"Marcotte","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib94","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ygyno.2011.04.008","article-title":"HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome","volume":"122","author":"Fagotti","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib95","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1245\/s10434-007-9648-5","article-title":"Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis","volume":"15","author":"Ceelen","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib96","first-page":"78","article-title":"Intraperitoneal hyperthermic chemotherapy for advanced gastrointestinal and ovarian cancers","volume":"2","author":"Loggie","year":"1994","journal-title":"Reg Cancer Treat"},{"key":"10.1016\/j.soc.2012.07.007_bib97","first-page":"185092","article-title":"Pharmacokinetic study of perioperative intravenous ifosfamide","volume":"2011","author":"Van der Speeten","year":"2011","journal-title":"Int J Surg Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib98","first-page":"5790","article-title":"Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies","volume":"50","author":"Sugarbaker","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.soc.2012.07.007_bib99","first-page":"2675","article-title":"Long term combination treatment with bevacizumab, pegylated liposomal doxorubicin and regional abdominal hyperthermia in platinum refractory ovarian cancer: a case report and review of the literature","volume":"31","author":"Pietzner","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.soc.2012.07.007_bib100","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/02656730500515270","article-title":"Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma","volume":"22","author":"Jones","year":"2006","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.soc.2012.07.007_bib101","first-page":"9","article-title":"Sodium arsenite and hyperthermia modulate cisplatin-DNA damage responses and enhance platinum accumulation in murine metastatic ovarian cancer xenograft after hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"4","author":"Muenyi","year":"2011","journal-title":"J\u00a0Ovarian Res"},{"key":"10.1016\/j.soc.2012.07.007_bib102","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/toxsci\/kfs085","article-title":"Sodium arsenite \u00b1 hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses","volume":"127","author":"Muenyi","year":"2012","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.soc.2012.07.007_bib103","unstructured":"States JC. Inhibition of HSP90 greatly enhances the efficacy of platinum-based therapies for ovarian cancer including hyperthermia. Abstract presented at Seventh International Symposium on Regional Cancer Therapies, Captiva Island (FL): February 2012."},{"key":"10.1016\/j.soc.2012.07.007_bib104","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","article-title":"Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study","volume":"18","author":"Muggia","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib105","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2012.07.007_bib106","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N\u00a0Engl J Med"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320712000567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320712000567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:56:37Z","timestamp":1760961397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320712000567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":106,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S1055320712000567"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2012.07.007","relation":{},"ISSN":["1055-3207"],"issn-type":[{"value":"1055-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Status and Future Directions of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Ovarian Cancer","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2012.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}